Abstract：
BACKGROUND: For clear cell renal cell carcinoma (ccRCC) with cystic component similar to multilocular cystic renal neoplasm of low malignant potential (MCRN-LMP) and solid low-grade component simultaneously, we propose the designation \"ccRCC with cystic component similar to MCRN-LMP\" and to study the relationship between MCRN-LMP and it.
METHODS: Twelve cases of MCRN-LMP and 33 cases of ccRCC with cystic component similar to MCRN-LMP were collected from 3,265 consecutive RCCs to compare them in clinicopathological features, immunohistochemical findings (PAX8, CA-IX, CK7, Vimentin, CD10, P504s, TFE3, 34βE12) and prognosis.
RESULTS: There was no significant difference in age, sex ratio, tumor size, treatment, grade and stage between them (P > 0.05). All ccRCCs with cystic component similar to MCRN-LMP coexisted with MCRN-LMP and solid low-grade ccRCCs, and MCRN-LMP component ranged from 20 to 90% (median, 59%). The positive ratio of CK7 and 34βE12 in MCRN-LMPs and ccRCCs\' cystic parts was significantly higher than that in ccRCCs\' solid parts, but the positive ratio of CD10 in MCRN-LMPs and ccRCCs\' cystic parts was significantly lower than that in ccRCCs\' solid parts (P < 0.05). There was no significant difference of all immunohistochemistry profiles between MCRN-LMPs and ccRCCs\' cystic parts (P > 0.05). No patient developed recurrence or metastasis.
CONCLUSIONS: MCRN-LMP and ccRCC with cystic component similar to MCRN-LMP have similarity and homology in clinicopathological features, immunohistochemical findings and prognosis, and form a low-grade spectrum with indolent or low malignant potential behavior. The ccRCC with cystic component similar to MCRN-LMP may be a rare pattern of cyst-dependent progression from MCRN-LMP.
METHODS: Twelve cases of MCRN-LMP and 33 cases of ccRCC with cystic component similar to MCRN-LMP were collected from 3,265 consecutive RCCs to compare them in clinicopathological features, immunohistochemical findings (PAX8, CA-IX, CK7, Vimentin, CD10, P504s, TFE3, 34βE12) and prognosis.
RESULTS: There was no significant difference in age, sex ratio, tumor size, treatment, grade and stage between them (P > 0.05). All ccRCCs with cystic component similar to MCRN-LMP coexisted with MCRN-LMP and solid low-grade ccRCCs, and MCRN-LMP component ranged from 20 to 90% (median, 59%). The positive ratio of CK7 and 34βE12 in MCRN-LMPs and ccRCCs\' cystic parts was significantly higher than that in ccRCCs\' solid parts, but the positive ratio of CD10 in MCRN-LMPs and ccRCCs\' cystic parts was significantly lower than that in ccRCCs\' solid parts (P < 0.05). There was no significant difference of all immunohistochemistry profiles between MCRN-LMPs and ccRCCs\' cystic parts (P > 0.05). No patient developed recurrence or metastasis.
CONCLUSIONS: MCRN-LMP and ccRCC with cystic component similar to MCRN-LMP have similarity and homology in clinicopathological features, immunohistochemical findings and prognosis, and form a low-grade spectrum with indolent or low malignant potential behavior. The ccRCC with cystic component similar to MCRN-LMP may be a rare pattern of cyst-dependent progression from MCRN-LMP.
摘要：
背景：对于囊性成分类似于多房性囊性肾肿瘤的低恶性潜能（MCRN-LMP）和实性低度成分的透明细胞肾细胞癌（ccRCC），我们建议命名为“具有类似于MCRN-LMP的囊性成分的ccRCC”，并研究MCRN-LMP与其之间的关系。
方法：从连续的3,265例RCC中收集12例MCRN-LMP和33例囊性成分与MCRN-LMP相似的ccRCC，以比较它们的临床病理特征。免疫组织化学发现（PAX8，CA-IX，CK7Vimentin,CD10,P504s,TFE3，34βE12)和预后。
结果：年龄无显著差异，性别比例,肿瘤大小,治疗,分级和分期之间(P>0.05)。所有囊性成分与MCRN-LMP相似的ccRCC与MCRN-LMP和固体低级别ccRCC共存，和MCRN-LMP成分范围为20％至90％（中位数，59%）。MCRN-LMPs和ccRCCs囊性部位CK7和34βE12阳性率明显高于ccRCCs实性部位,但MCRN-LMPs和ccRCCs囊性部位CD10阳性率明显低于ccRCCs实性部位(P<0.05)。MCRN-LMPs和ccRCCs囊性部位的所有免疫组织化学谱均无显着差异（P>0.05）。无复发或转移。
结论：MCRN-LMP和具有与MCRN-LMP相似的囊性成分的ccRCC在临床病理特征上具有相似性和同源性，免疫组织化学结果和预后，并形成具有惰性或低恶性潜在行为的低度光谱。具有类似于MCRN-LMP的囊性成分的ccRCC可能是MCRN-LMP的囊肿依赖性进展的罕见模式。
方法：从连续的3,265例RCC中收集12例MCRN-LMP和33例囊性成分与MCRN-LMP相似的ccRCC，以比较它们的临床病理特征。
结果：年龄无显著差异，
结论：MCRN-LMP和具有与MCRN-LMP相似的囊性成分的ccRCC在临床病理特征上具有相似性和同源性，
